<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266720</url>
  </required_header>
  <id_info>
    <org_study_id>689</org_study_id>
    <nct_id>NCT01266720</nct_id>
  </id_info>
  <brief_title>HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)</brief_title>
  <official_title>Phase 1 Study of HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fukushima Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fukushima Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpuse of this study is to assess toxicities of angiogenic peptide vaccine therapy with
      gemcitabine in treating HLA-A*0201 restricted patient with non-resectable pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prognosis of pancreatic cancer is extremely poor even with extensive surgery,
      chemotherapy or radiation. It has been required development of new treatment modalities.
      Immunotherapy is one of the encouraging modalities for cancer patients. The investigators
      have to assess its toxicities and immune responsiveness.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities as assessed by NCI-CACAE ver3</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences of peptide specific CTL response in vitro among sequence of gemcitabine and peptide vaccine administration</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8 population</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of regulatory T cells</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1 study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions:
Biological: VEGFR1, VEGFR2 Drug: Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VEGFR1, VEGFR2</intervention_name>
    <description>One mg of each peptide will be administered subctaneously on days 1, 8, 15 and 22</description>
    <arm_group_label>Phase 1 study</arm_group_label>
    <other_name>VEGFR1 and VEGFR2 specific epitope vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, 15.</description>
    <arm_group_label>Phase 1 study</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  locally advanced or metastatic pancreatic cancer precluding curative surgical
             resection and recurrent pancreatic cancer

          -  Measurable disease by CT scan

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 3 months

          -  laboratory values as follows: 2,000/mm3 &lt; WBC &lt; 15,000/mm3, Platelet count
             &gt;75,000/mm3, Total Bilirubin &lt;1.5 mg/dl, Asparate transaminase &lt;150IU/L, Alanine
             transaminase &lt; 150 IU/L, Creatinine &lt; 3.0mg/dl

          -  HLA-A*0201

          -  Able and willing to give valid written infromed consent

        Exclusion Criteria:

          -  Pregnancy (women of childbearing potential: Refusal or inability to use effective
             means of contraception)

          -  Breast-feeder

          -  Active or uncontrolled infection

          -  Prior chemotherapy, radiation therapy, or immunotherapy within 4 weeks

          -  Serious or uncured wound

          -  Active or uncontrolled other malignancy

          -  Steroids or immunosuppressing agent dependent status

          -  Interstitial pneumonia

          -  Ileus

          -  Decision of unsuitableness by principal investigator or physician-in-charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsukazu Gotoh, MD &amp; PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fukushima Medical University, Department of Regeneration Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002 Dec;8(12):1369-75. Epub 2002 Nov 4.</citation>
    <PMID>12415261</PMID>
  </reference>
  <reference>
    <citation>Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9.</citation>
    <PMID>17020992</PMID>
  </reference>
  <reference>
    <citation>Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46.</citation>
    <PMID>15930316</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>December 23, 2010</last_update_submitted>
  <last_update_submitted_qc>December 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Fukushima Medical University (Department of Regeneration Surgery)</name_title>
    <organization>Fukushima Medical University</organization>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>peptide vaccine</keyword>
  <keyword>VEGFR</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

